NCT06579703Not yet recruitingPhase 4
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Ketorolac Dosing for Acute Vaso-Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
Source: ClinicalTrials.gov · Last updated 30 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg/kg/dose IV (\<16yo max 15mg, \>16yo max 30mg) x 1 dose.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- First submitted
- 24 Jul 2024
- Start date
- 30 Sept 2024
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Children's Blood and Cancer Center at Dell Children's Medical Center
- Diseases
- Sickle cell disease
- NCT number
- NCT06579703
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 102
- From 30 Sept 2024 to the primary completion date, 1 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving NSAID medication \<6 hours from presentation
Other illness
- bleeding concerns
- allergy to NSAID medication
Other
- known kidney injury
- sickle nephropathy
- chronic pain patient
- hemodynamic instability as defined by the treating provider
Who the study is looking for
- Pediatric patients with sickle cell disease (any genotype) who present to DCMC Emergency department or outpatient hematology clinic with acute pain.
Age in the registry: 1 day to 21 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.